论文部分内容阅读
美国Corixa公司和GSK Bio公司将开始新的预防性结核病( TB)疫苗的 期研究。 这种疫苗联有一种重组结核杆菌蛋白抗原,此抗原是从不同结核杆菌基因产物中获得的抗原区的融合蛋白。抗原区取自于无症状结核杆菌感染者的免疫细胞。这种疫苗还以GSK Bio公司的专门配方为特色,这种
Corixa and GSK Bio in the United States will begin a phase-out of a new prophylactic tuberculosis (TB) vaccine. This vaccine is associated with a recombinant Mycobacterium tuberculosis antigen that is a fusion protein in the antigenic region obtained from different Mycobacterium tuberculosis gene products. The antigen zone is taken from immune cells infected with asymptomatic Mycobacterium tuberculosis. This vaccine also features GSK Bio’s proprietary formula, this